1 Green Flag for AbbVie (ABBV) Stock Right Now That Even Crypto Bulls Can’t Ignore

Pharma giant AbbVie just flashed a bullish signal that's getting traditional investors excited—and crypto traders might want to pay attention too.

Strong Fundamentals in a Volatile Market

While altcoins swing wildly on Elon Musk tweets, ABBV's steady revenue stream and dividend performance offer something rare in today's markets: predictability. No shady tokenomics, just cold hard cash flow.

Institutional Money Moving In

Big funds are stacking ABBV like it's Bitcoin in 2017—except with FDA approvals instead of white papers. The stock's resilience during recent market chaos has Wall Street nodding approval while crypto bros cope with another -20% day.

Because sometimes the smartest trade is the boring one that doesn't require checking charts every five minutes.

Image source: Getty Images.

AbbVie's payout ratio -- the percentage of earnings paid out in dividends -- is quite reasonable, too, at less than 50%. That leaves plenty of room for further increases.

Like other pharmaceutical companies, AbbVie has faced the loss of patent protection for various drugs over time, most notably for its blockbuster Humira. But that was never a surprise, and AbbVie has around 90 treatments in its pipeline, having invested nearly $11 billion in research and development in 2024 alone. The majority of those treatments are in the mid to late stages of development.

AbbVie's stock has averaged annual gains of 15.8% over the past decade, and its future is quite promising. But with a forward-looking price-to-earnings (P/E) ratio of 15 at the moment (well above the five-year average NEAR 12), shares aren't a screaming bargain. You might want to wait and hope for a lower price -- or just buy into the stock gradually over time.